These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 26603719)

  • 1. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
    Giraldo P; Pérez-López J; Núñez R; de la Puebla RF; Luño E; Saura-Grau S; Bureo JC; Plaza S; de la Serna J
    Blood Cells Mol Dis; 2016 Jan; 56(1):23-30. PubMed ID: 26603719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
    Weinreb N; Taylor J; Cox T; Yee J; vom Dahl S
    Am J Hematol; 2008 Dec; 83(12):890-5. PubMed ID: 18819093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comprehensive Study of Bone Manifestations in Adult Gaucher Disease Type 1 Patients in Argentina.
    Oliveri B; González D; Quiroga F; Silva C; Rozenfeld P
    Calcif Tissue Int; 2019 Jun; 104(6):650-657. PubMed ID: 30790003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
    Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
    PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
    Mistry PK; Balwani M; Charrow J; Lorber J; Niederau C; Carwile JL; Oliveira-Dos-Santos A; Perichon MG; Uslu Cil S; Kishnani PS
    Am J Hematol; 2024 Aug; 99(8):1500-1510. PubMed ID: 38686876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.
    Herrera S; Pérez-López J; Moltó-Abad M; Güerri-Fernández R; Cabezudo E; Novelli S; Esteve J; Hernández A; Roig I; Solanich X; Prieto-Alhambra D; Nogués X; Díez-Pérez A
    J Bone Miner Res; 2017 Jul; 32(7):1575-1581. PubMed ID: 28263001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial.
    Lukina E; Watman N; Dragosky M; Lau H; Avila Arreguin E; Rosenbaum H; Zimran A; Foster MC; Gaemers SJM; Peterschmitt MJ
    Am J Hematol; 2019 Jan; 94(1):29-38. PubMed ID: 30264864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical characteristics of type I Gaucher's disease in Spain. Preliminary results of national survey. Spanish Group on Gaucher's Disease].
    Giraldo P; Pérez-Calvo JI; Giralt M; Pocovi M
    Med Clin (Barc); 1997 Nov; 109(16):619-22. PubMed ID: 9463135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of Bone Marrow Involvement in Treated Gaucher Disease With Proton MR Spectroscopy: Correlation With Bone Marrow MRI Scores and Clinical Status.
    Jaramillo D; Bedoya MA; Wang DJ; Pena AH; Delgado J; Jaimes C; Ho-Fung V; Kaplan P
    AJR Am J Roentgenol; 2015 Jun; 204(6):1296-302. PubMed ID: 26001241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of magnetic resonance imaging for bone involvement in Gaucher disease. Assessing more than bone crises.
    Andrade-Campos M; Valero E; Roca M; Giraldo P;
    Blood Cells Mol Dis; 2018 Feb; 68():126-134. PubMed ID: 27836527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
    Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
    Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Quality study of diagnostic and follow-up procedures of bone involvement in type 1 Gaucher"s disease in Spain].
    Pérez Calvo JI; Giraldo Castellano P; Rubio-Félix D; Giralt Reichs M; Pocoví Mieras M
    An Med Interna; 2003 Dec; 20(12):607-11. PubMed ID: 14697079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
    Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
    Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
    Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
    Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project.
    Serrano-Gonzalo I; de Frutos LL; Lahoz-Gil C; Delgado-Mateos F; Fernández-Galán MÁ; Morales-Conejo M; Calle-Gordo MV; Ibarretxe-Gerediaga D; Madinaveitia-Ochoa A; Albarracin-Arraigosa A; Balanzat-Muñoz J; Correcher-Medina P; García-Frade LJ; Hernández-Rivas JM; Labbadia F; López-Dupla JM; Lozano-Almela ML; Mora-Casterá E; Noya-Pereira MS; Ruíz-Guinaldo MÁ; Del Mar Tormo-Díaz M; Vitoria-Miñana I; Arévalo-Vargas I; Andrade-Campos M; Giraldo P
    Orphanet J Rare Dis; 2023 Dec; 18(1):390. PubMed ID: 38102667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1.
    Lorenz F; Pawłowicz E; Klimkowska M; Beshara S; Bulanda Brustad A; Skotnicki AB; Wahlin A; Machaczka M
    Blood Cells Mol Dis; 2018 Feb; 68():35-42. PubMed ID: 27816428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.